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Immunogenicity and Protective Efficacy against Enterotoxigenic
Escherichia coli Colonization following Intradermal, Sublingual, or
Oral Vaccination with EtpA Adhesin
Qingwei Luo,a Tim J. Vickers,a James M. Fleckensteina,b,c
Department of Medicine, Division of Infectious Diseases,a and Molecular Microbiology and Microbial Pathogenesis Program,b Washington University School of Medicine,
Saint Louis, Missouri, USA; Medicine Service, Veterans Affairs Medical Center, Saint Louis, Missouri, USAc
Enterotoxigenic Escherichia coli (ETEC) strains are a common cause of diarrhea. Extraordinary antigenic diversity has
prompted a search for conserved antigens to complement canonical approaches to ETEC vaccine development. EtpA, an immu-
nogenic extracellular ETEC adhesin relatively conserved in the ETEC pathovar, has previously been shown to be a protective an-
tigen following intranasal immunization. These studies were undertaken to explore alternative routes of EtpA vaccination that
would permit use of a double mutant (R192G L211A) heat-labile toxin (dmLT) adjuvant. Here, oral vaccination with EtpA adju-
vanted with dmLT afforded significant protection against small intestinal colonization, and the degree of protection correlated
with fecal IgG, IgA, or total fecal antibody responses to EtpA. Sublingual vaccination yielded compartmentalized mucosal im-
mune responses with significant increases in anti-EtpA fecal IgG and IgA, andmice vaccinated via this route were also protected
against colonization. In contrast, while intradermal (i.d.) vaccination achieved high levels of both serum and fecal antibodies
against both EtpA and dmLT, mice vaccinated via the i.d. route were not protected against subsequent colonization and the avid-
ity of serum IgG and IgA EtpA-specific antibodies was significantly lower after i.d. immunization compared to other routes. Fi-
nally, we demonstrate that antiserum from vaccinated mice significantly impairs binding of LT to cognate GM1 receptors and
shows near complete neutralization of toxin delivery by ETEC in vitro. Collectively, these data provide further evidence that
EtpA could complement future vaccine strategies but also suggest that additional effort will be required to optimize its use as a
protective immunogen.
Enterotoxigenic Escherichia coli (ETEC) strains are among themost common causes of diarrheal illness in developing coun-
tries, where young children are most susceptible (1, 2). In addi-
tion, these pathogens are also a common cause of diarrhea in
immunologically naive travelers (3) who venture to areas of ende-
micity where sanitation and clean water remain limited.
Given the significant impact of ETEC on global health, a vac-
cine to prevent these infections is a significant priority (4). How-
ever, despite decades of investigative efforts following the discov-
ery of toxin-producing E. coli in patients with clinical illnesses
indistinguishable from cholera (5), a vaccine that affords broad-
based protection has yet to be developed.
All of the ETEC-specific virulence genes described to date are
encoded on plasmids. These include the heat-labile and/or heat-
stable enterotoxins that define this pathovar and the colonization
factors (CFs). Most vaccines to date have primarily targeted these
colonization factors, which include a broad array of fimbrial as
well as afimbrial surface antigens thought to be essential for intes-
tinal colonization and/or heat-labile toxin.
Unfortunately, the heterogeneity of CF antigenic structures
presents a challenge to development of a broadly protective vac-
cine.While some antigens are more conserved and widely distrib-
uted geographically and across different phylogenic backgrounds
(6), the inherent plasticity ofE. coli genomes (7, 8) and the fact that
many ETEC strains do not make one of the 26 different CFs de-
scribed to date (9, 10) have prompted a search for additional an-
tigens that might also be considered to complement existing vac-
cine development paradigms (11).
Among antigens under investigation as a putative vaccine can-
didate is EtpA. This plasmid-encoded secreted glycoprotein be-
longs to the two-partner secretion family of molecules that
includes filamentous hemagglutinin (FHA), a component of
acellular pertussis vaccines (12). Studies of EtpA to date have
demonstrated that it plays a unique role in facilitating ETEC ad-
hesion and toxin delivery to target intestinal epithelial cells (13).
Moreover, experiments with mice have shown that EtpA pro-
motes colonization of the small intestine and can serve as a pro-
tective antigen (13, 14).
Recent molecular characterization of strains from a variety of
sources has also suggested that EtpA is sufficiently conserved to
warrant further consideration as a potential vaccine antigen (7, 15,
16). Early proof-of-principal studies with EtpA were conducted
using an intranasal route of vaccinationwith Protollin (14, 17–19)
or heat-labile toxin (LT) (20). However, because LT is not safe for
intranasal vaccination in humans (21, 22), and because an LT
toxoid will likely be a key component of next-generation vaccines,
here we investigated the immunogenicity and protective efficacy
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of EtpA when delivered by other routes using a double mutant
(R192G L211A) heat-labile toxin (dmLT) as the adjuvant.
MATERIALS AND METHODS
Adjuvant and immunogen preparation. The double mutant (R192G
L211A) heat-labile toxin (dmLT) (23) used in these studies was manufac-
tured by the Bioproduction Facility at Walter Reed Army Institute for
Research, Silver Spring, MD (BPR-1037-00, lot no. 1735) and was stored
lyophilized at20°C prior to use. dmLT was reconstituted to 1 mg/ml in
sterile phosphate-buffered saline (PBS) immediately before use and then
diluted as needed with PBS. Recombinant polyhistidine-tagged EtpA gly-
coprotein (rEtpA) was purified as previously described using metal affin-
ity chromatography from culture supernatants of an E. coli TOP10 strain
transformed with pJL017 and pJL030 (jf1696) (Table 1) (24). Briefly,
overnight cultures grown from frozen glycerol stocks maintained at
80°C were diluted 1:100 into fresh Luria broth (LB) containing final
concentrations of 100 g/ml ampicillin and 15 g/ml chloramphenicol
and grown at 37°C to an optical density at 600 nm (OD600) of 0.6.
Arabinose (0.0002%)was then added to induce EtpA expression. After 3 h
of induction, cultures were harvested at 6,000 rpm at 4°C for 10 min, and
supernatant was filtered and saved for subsequent purification. Superna-
tant was concentrated 10-fold using a Pellicon concentrator with
30,000-molecular-weight (MW) cutoff (Millipore). After being loaded
onto metal affinity columns (5 ml; HiTrap, GE), unbound protein was
removed by washing with buffer containing 25 mM sodium phosphate,
300mMsodiumchloride (pH7.4), and 0 to 100mMimidazole. rEtpAwas
then eluted from the column in the same buffer over a gradient ranging
from 100 to 600 mM imidazole. Eluate fractions containing rEtpA were
pooled and then concentrated with an Amicon Ultra-15 Ultracel-100k
centrifuge (Millipore), and the buffer was exchanged with PBS (pH 7.4)
before being stored at80°C. rEtpA and dmLT were combined immedi-
ately prior to vaccination.
Immunization protocols. Female CD-1 mice (5 to 8 weeks old) were
purchased fromCharles River Laboratories. Groups of 10 to 12mice were
vaccinated on days 1, 29, and 43 via the sublingual, intradermal (i.d.), or
orogastric routes, with additional vaccination given on day 57 by the sub-
lingual route only. Before vaccination,mice were lightly anesthetizedwith
isoflurane. For orogastric vaccination, mice were first fasted for 2 h and
then gavaged with 100 l of NaHCO3 (7.5%) to neutralize stomach acid.
After 5min, mice were then gavaged with the vaccine or controls in a final
volume of 300 l of PBS. For sublingual vaccination, 10 l of the prepa-
ration was pipetted under the tongue, and the head was maintained up-
right until the mouse regained consciousness. For intradermal vaccina-
tion, an alcohol swab was used to wet and separate abdominal fur, after
which 50 l of the vaccine preparation or control solution was delivered
intradermally using a 1/2-ml insulin syringe fitted with a 29-gauge needle.
To confirm intradermal placement of the antigen, we performed test i.d.
injections of tattoo ink in parallel sets of live CD-1 mice. Sections of skin
were subsequently processed for hematoxylin and eosin staining and ex-
amination by light microscopy.
Orogastric vaccination employed 25 g of dmLT in adjuvant-only
controls and as the adjuvant with doses of either 200 or 400 g of rEtpA.
Sublingual vaccination used 5 g of dmLT/mouse  10 g of EtpA. In-
tradermal vaccination was done in two experiments with doses of either
100 ng of dmLT 250 ng of rEtpA or 1 g of dmLT 2.5 g of rEtpA.
Sample collection. Mouse fecal samples were collected 2 weeks after
each boost. Six fecal pellets from each mouse were resuspended in 1.5 ml
of fecal resuspension buffer (containing 10 mMTris base, 100 mMNaCl,
0.05% Tween 20, and 5 mM sodium azide, pH 7.4) and stored at 4°C
overnight. Mouse serum samples were collected either from abdominal
aorta or from terminal cardiac bleeds using 25-gauge tuberculin syringes.
Bacterial strains and growth conditions. Strain jf876, a derivative of
ETEC strainH10407 bearing a kanamycin resistancemarker in the lacZYA
locus (lacZYA::kan) (Table 1) was used in all colonization experiments as
previously described (25). Briefly, jf876 maintained as a frozen glycerol
stock at80°C was used to inoculate sterile Luria broth (LB). After over-
night growth at 37°C at 225 rpm, the culture was diluted 1:100 into fresh
LB medium, grown to an OD600 of0.3, and serially diluted to an inoc-
ulum of105 to 106 for challenge.
Intestinal colonization studies in mice. Intestinal colonization ex-
periments were performed as previously described (25). Briefly, prior to
challenge, mice were pretreated with streptomycin (5 g/liter) in drinking
water for 24 h, followed by regular water for 12 h, and famotidine (50
mg/kg body weight) was given 1 to 3 h prior to challenge to neutralize
stomach acid. Mice were then challenged with105 CFU of ETEC bacte-
ria by oral gavage (25). Twenty-four hours after challenge, mice were
sacrificed and two 3-cm sections of small intestine (ileum) were collected
as previously described. Following incubation in saponin (5%) for 10
min, dilutions of intestinal lysates in PBS were plated onto Luria agar
plates containing kanamycin (50 g/ml). Following overnight incuba-
tion, bacteria were enumerated by counting kanamycin-resistant colo-
nies. All experiments with mice were performed under protocols ap-
proved by the Animal Studies Committee at Washington University
School of Medicine.
Immunologic assessment. A kinetic enzyme-linked immunosorbent
assay (ELISA) was used to detect immune responses in both fecal and
serum samples as previously described (15). Briefly, 96-well plates were
coated with 0.1 g/well of EtpA or GM1 gangliosides (Sigma; catalog no.
G2375) in carbonate buffer (15mMNa2CO3, 35mMNaHCO3, 0.2 g/liter
NaN3, pH 8.6) overnight at 4°C. After washing, dmLT (1 g/ml in PBS)
was added to wells containing GM1 gangliosides and incubated for 1 h at
37°C. Plates were washed and blocked with 1% bovine serum albumin
(BSA) for 1 h at 37°C. Plates were again washed and then incubated with
fecal extracts (undiluted) orwith sera (diluted 1:100 in PBS containing 1%
BSA). After incubation at 37°C for 1 h, plates were washed and incubated
with horseradish peroxidase (HRP)-secondary antibody conjugates for 30
min at 37°C. After washing, TMB (3,3=,5,5=-tetramethylbenzidine)-per-
oxidase substrate (KPL) was added, and plates were immediately read at
650 nm to collect kinetic ELISA data (26). Data were analyzed using Gen5
software (BioTek) and are reported as Vmax (milliunits per minute).
Serum EtpA antibody avidity determinations. Avidity indexes for
EtpA-specific serum IgG and IgA antibodies were determined as previ-
ously described (27). Briefly, microtiter wells were coated with EtpA as
described above. After being washed and blocked, plates were incubated
with sera diluted 1:10,000 at 37°C for 1 h. Plates were washed and then
incubated with either 6 M urea solution or PBS for 10 min at 37°C. After
being washed, plates were incubated with either anti-mouse IgA or anti-






H10407 Wild-type ETEC strain O78:H11; CFA/1 LT
ST EtpA
57, 58
jf570 eltAB LT deletion mutant of H10407 59
jf876 lacZYA::Kmr mutant of H10407 59
jf1696 TOP10(pJL017, pJL030) Ampr Cmr 24
TOP10 FmcrA (mrr-hsdRMS-mcrBC) 80lacZM15
lacX74 recA1 araD139 (ara leu)7697 galU
galK rpsL (Strr) endA1 nupG
Invitrogen
Plasmids
pJL017 etpBA cloned into pBAD/myc-His A, with etpA
in frame with myc and 6His coding regions;
Ampr
14
pJL030 etpC gene cloned into pACYC184; Cmr 13
a Kmr, kanamycin resistant; Cmr, chloramphenicol resistant; Ampr, ampicillin resistant;
Strr, streptomycin resistant.
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FIG 1 Immunogenicity and inhibition of intestinal colonization following oral immunization with EtpA adjuvanted with dmLT. (a to f) Kinetic ELISA data
demonstrating fecal antibody responses to dmLT (a to c) and EtpA (d to f) following oral immunization with dmLT adjuvant alone (25 g), 25 g dmLT plus
200g rEtpA, or 25g dmLTplus 400g rEtpA. The antigen and antibody isotype tested are shown in the upper left-hand corner of each graph. Serum responses
(IgG) at a dilution of 1:100 are shown for (g) dmLT and (h) EtpA, and panels i and j correspond to serum IgA responses. (k) Intestinal colonization inmice (grey
symbols represent individual mice) following challenge with enterotoxigenic E. coli. Dashed horizontal lines in each figure panel represent geometric means.
Comparisons to the PBS control group were made by Mann-Whitney nonparametric testing (*, P	 0.05; ***, P	 0.001; ****, P	 0.0001).
Luo et al.
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mouse IgG HRP-conjugated secondary antibody, and responses were de-
termined by kinetic ELISA as described above. Avidity indexes were then
calculated as the ratio of the Vmax (milliunits per minute) in the urea-
treated wells to that in the untreated wells.
Toxin neutralization assays. To examine the ability of antisera to
prevent binding of heat-labile toxin to its receptor, plateswere coatedwith
GM1 gangliosides at a 1-g/ml final concentration in PBS overnight at
4°C. Serum from vaccinated or control mice was diluted 1:128 in PBS and
then incubated 1:1 with LT at a final concentration of 1 g/ml at 4°C
overnight. After washing of plates with PBS, LT preincubated with serum
was then allowed to bind to target gangliosides for 1 h at 37°C. Plates were
then washed and blocked with 1% BSA for 1 h at 37°C. Bound LT was
determined by anti-LT-B kinetic ELISA. Briefly, plates were incubated
using primary anti-LT-B rabbit polyclonal antiserum diluted 1:1,000 in
PBS containing 1% BSA at 37°C for 1 h and washed, followed by addition
of goat anti-rabbit IgG-HRP conjugate diluted 1:5,000 in 1% BSA at 37°C
for 30 min. After the final washing, plates were developed with TMB
substrate and data collected kinetically as described above.
To examine the ability of antisera from immunized animals to prevent
effective toxin delivery by ETEC, a 96-well tissue culture plate was first
seeded with Caco-2 cells and the culture was grown at 37°C in 5% CO2
until the cells formed a confluent monolayer. One microliter of a mid-
logarithmic-phase Luria broth culture of H10407 was then added with 10
l of sera from individual mice and incubated with target Caco-2 mono-
layers at 37°C in 5% CO2. After 2.5 h, plates were washed with preequili-
brated tissue culturemedium, then incubated for an additional 2 h at 37°C
in 5% CO2, and finally washed 4 times with PBS. Cyclic AMP (cAMP)
activation in target epithelial cells was then determined by ELISA (De-
tectX direct cyclic AMP kit; Arbor Assays, Ann Arbor, MI).
RESULTS
Immunogenicity and protective efficacy following oral vaccina-
tion with EtpA. Because dmLT has been given safely to human
volunteers via the oral route (28), we first examinedwhether EtpA
could afford protection when coadministered with dmLT as the
adjuvant. Following oral immunization, micemounted robust fe-
cal IgA, fecal IgG, and total fecal antibody responses to the dmLT
adjuvant, whether administered alone or in combination with
EtpA (Fig. 1a to c). Likewise, we observed significant amounts of
anti-EtpA fecal antibodies compared to either dmLT-only or PBS
controls (Fig. 1d to f). Oral vaccination also resulted in demon-
strable increases in serum IgG and IgA antibodies against dmLT
(Fig. 1g and i) and against EtpA (Fig. 1h and j).
Following oral vaccination, mice in the EtpA vaccine adminis-
tration group had significantly lower levels of intestinal coloniza-
tion than either PBS controlmice or dmLTadjuvant-only controls
(Fig. 1k). While mice immunized with the highest dose of EtpA
exhibited the lowest geometric mean number of CFU of ETEC in
the small intestine, the difference between EtpA low- and high-
dose groups was not statistically significant.
Correlation between protection and fecal antibody produc-
tion. Theoretically, vaccines against enteric pathogens should en-
gendermucosal antibodies that neutralize the ability of the patho-
gen to colonize the host and/or to deliver its effector molecules.
Because EtpA functions as an adhesin, we examined the correla-
tion between the levels of fecal antibody levels achieved in indi-
vidual mice following vaccination and intestinal colonization.
Levels of intestinal IgG (Fig. 2a) and IgA (Fig. 2b) were both re-
lated to reductions in intestinal colonization, while the strongest
correlation (P 
 0.005) was observed with total fecal antibody
levels (Fig. 2c).
Sublingual administration of EtpA with dmLT. Previous
studies have shown that sublingual administration of antigens can
induce both systemic and mucosal antibody responses with doses
that are appreciably smaller than those required for oral adminis-
tration (29). Similar to oral administration, sublingual vaccina-
tion with the combination of dmLT and EtpA also stimulated
production of fecal IgG (Fig. 3a) and fecal IgA (Fig. 3b) as well as
serum IgG (Fig. 3c) and serum IgA (Fig. 3d) antibodies to the
dmLT adjuvant. Although sublingual vaccination resulted in
modest increases in responses to EtpA in feces (Fig. 3e and f), there
was no significant increase in serum antibodies (Fig. 3g and h),
consistent with compartmentalization of the mucosal immune
response. While vaccination of mice sublingually with EtpA adju-
vanted with dmLT did afford some protection against coloniza-
tion relative to unvaccinated mice (Fig. 3i), we did not observe a
significant correlation between fecal antibody levels and the level
of intestinal colonization (Fig. 3j).





































r=-0.34 (p=0.019) r=-0.37 (p=0.0097) r=-0.4 (p=0.005)
fecal IgA fecal IgG fecal ab (total)
FIG 2 Correlation of anti-EtpA fecal antibody levels and intestinal colonization in mice following oral vaccination. (a) Comparison of IgA anti-EtpA fecal
antibody levels and colonization. (b) Fecal IgG versus colonization. (c) Total fecal antibody (ab) (IgG, IgM, and IgA) versus colonization. The results of Spearman
(nonparametric) correlation coefficient (r) and corresponding P value are shown in the upper left-hand corner of each graph. Each point represents data from
a total of 47 mice, including PBS controls (n 
 12), dmLT adjuvant-only controls (n 
 12), mice administered dmLT plus 200 g EtpA (n 
 11), and mice
administered dmLT plus 400 g EtpA (n
 12).
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vaccine required to achieve an immunologic response is typically
several orders ofmagnitude smaller with i.d. vaccination than that
required for other routes, offering significant dose sparing. More-
over, the emergence of needle-free technologies (30, 31) could
make this route feasible for deployment to developing countries,
where cost and ease of administration are important consider-
ations. Therefore, we also examined intradermal vaccination with
EtpA in mice. After verification of intradermal placement of po-
tential immunogens (see Fig. S1 in the supplementalmaterial), we
were able to achieve high titers of both serum and fecal antibodies
to both the adjuvant (Fig. 4a to d) and the EtpA immunogen (Fig.
4e to h) following intradermal administration. Curiously, how-
ever, we saw no significant protection against colonization when
mice were vaccinated via the i.d. route (Fig. 4g), suggesting that
the route of administration could have a substantial impact on
vaccine efficacy.
Because intradermal vaccination resulted in high titers of an-
tibody that did not protect against intestinal colonization, we
questioned whether the quality of antibody frommice vaccinated
intradermally differed from that of mice vaccinated orally. Anti-
body avidity, which examines the functional affinity of antibody-
antigen interactions, has been used as marker of B cell maturation
and a surrogate of protective immunity to a number of important
pathogens. Importantly, antibody avidity has been shown to cor-
relate with the presence of antigen-specificmemory B cells follow-
ing Vibrio cholerae infection (27), potentially permitting efficient
measurement of responses that might predict protection against a




























































































































































































































































FIG 3 Immunogenicity and inhibition of intestinal colonization following sublingual immunization with EtpA adjuvanted with dmLT. (a and b) Fecal IgG (a)
and fecal IgA (b) responses to the dmLTadjuvant. (c andd) Serum IgG (c) and serum IgA (d) responses to dmLT. (e and f) Fecal IgG (e) and fecal IgA (f) responses
to rEtpA. (g and h) Serum IgG (g) and serum IgA (h) responses to rEtpA. (i) Colonization ofmice following vaccinationwith rEtpA adjuvantedwith dmLT versus
dmLT alone or PBS controls. (j) Correlation between fecal IgA and intestinal colonization following sublingual vaccination. Comparisons between groups were
made by Mann-Whitney nonparametric testing (*, P	 0.05; ***, P	 0.001; ****, P	 0.0001).
Luo et al.
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rum IgG antibody avidity in the intradermally vaccinated mice
was considerably lower than that in the mice vaccinated orally
with EtpA (P 
 0.002) (Fig. 5a), as was the EtpA-specific IgA
avidity index (AI) (Fig. 5b). Collectively, these data suggest that
further assessment of immunization routes, timing of administra-
tion, and doses of antigen and adjuvant will likely be important
considerations in optimizing the protective efficacy of more re-
cently described antigens, including EtpA.
Toxin neutralization by sera from vaccinated mice. Because
immunization using dmLT as the adjuvant resulted in significant
production of anti-LT antibody, we also examined whether the
antibodies were functionally relevant. As demonstrated in Fig. 6a,
sera frommice immunized using dmLT prevented effective bind-
ing of wild-type heat-labile toxin to target GM1 gangliosides in
vitro relative to sera from PBS control mice. Importantly, we
found that antisera from either mice immunized with dmLT ad-
juvant only or frommice immunized with recombinant EtpA and





































































































































































































































FIG 4 Intradermal vaccination with EtpA results in significant increases in fecal and serum antibody without substantial protection. Shown in panels a to h are
kinetic ELISA data expressed as Vmax (milliunits per minute) obtained with clarified fecal suspensions (at a 1:1 dilution) or serum (diluted 1:100). (a to d) Fecal
IgG (a), IgA (b), serum IgG (c), and serum IgA (d) antibody responses to the dmLT adjuvant. (e to h) Fecal IgG (e), fecal IgA (f), serum IgG (g), and serum IgA
(h) antibody responses to EtpA. (i)Mouse colonization following vaccination with EtpA and dmLT adjuvant compared to adjuvant-alone or PBS-only controls.
Comparisons between groups were made by Mann Whitney (two-tailed) nonparametric testing (**, P	 0.01; ****, P	 0.0001).
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ETEC strain H10407, as determined by activation of cAMP in
target Caco-2 epithelial cell monolayers (Fig. 6b). These data pro-
vide further evidence vaccines combining novel adhesin and tox-
oid approaches could offer a viable strategy to protect against
ETEC.
DISCUSSION
Construction of ETEC vaccines has been hampered in part by the
extraordinary genetic plasticity of E. coli confounding efforts to
define the ideal group of antigens that will achieve broad-based
protection. Vaccines currently under study attempt to confront
this challenge by using multiple live attenuated strains (32) or
whole-cell killed strains that each present different CF antigens
and are combined with mutant forms or subunits of heat-labile
toxin (28). Interestingly, recent studies of more than 800 iso-
lates from ETEC diarrhea cases in Bangladesh demonstrated
that only approximately half of the strains expressed coloniza-
tion factors (CFs) that could be identified by immunoassays
(33), and new CF antigens continue to be identified by genomic
sequencing (34).
The potential complexity of vaccines based exclusively on clas-
sical ETEC targets has driven investigation of other antigens com-
mon to the ETEC pathovar. Theoretically, these antigens, not cur-
rently part of ETEC vaccine platforms, could be incorporated into
future iterations of vaccines to expand antigenic valency and per-
haps act in concert with canonical ETEC vaccine targets to en-
hance efficacy. One potential alternative target is the two-partner
secretion system that encodes EtpA. This system, originally dis-
covered by transposon mutagenesis of the prototype H10407
strain (12), appears to be relatively conserved within the ETEC
pathovar (7, 15, 16). EtpA-specific antibodies are present in hu-
man convalescent-phase sera, suggesting that this protein is ex-
pressed during the course of infection and is immunogenic (15,
35). These features and the molecular and functional similarity of
EtpA to filamentous hemagglutinin (36), a component of acellular
pertussis vaccines (37), have prompted preclinical investigation of
the utility of EtpA as a protective antigen. Multiple studies with
mice have now demonstrated that EtpA vaccination protects
against colonization of the small intestine (14, 19, 20), thought to
be a critical determinant of ETEC diarrheal illness. Another con-
sideration driving the present studies is that ETEC and Shigella are
among the most common bacterial pathogens causing serious di-
arrheal illness among young children in developing countries;
therefore, we questioned whether subunit approaches presently
being developed for Shigella effectors (38, 39) could be also ap-
plied to novel secreted ETEC antigens, including EtpA.
Because all prior studies of this target antigen to date have
involved intranasal immunization, we examined whether we
might be able to deliver EtpA by other means and elicit protective
immune responses. These most recent studies provide further ev-
idence that EtpA affords protection against intestinal colonization
and that this antigen retains substantial immunogenicity when
administered by a variety of different routes.
Perhaps not surprisingly, however, protective efficacy varied
with the route of administration (40, 41), and despite substantial
antibody responses following i.d. immunization, we did not
achieve protection. One possible explanation for these seemingly
discordant results is that the levels of quality of antibodies gener-
ated in different vaccination protocols could differ substantially.
Antibody avidity is thought to represent the overall strength of
binding by a polyvalent collection of antibodies to a variety of
antigenic determinants and to reflect development of germinal
center B cell antibody affinity maturation (42). A number of clin-
ical studies have correlated antibody avidity with vaccine protec-
tive efficacy (43–45), and conversely low antibody avidity and
poor affinity maturation have previously been associated with
vaccine failures (46–50). The current studies seem to support the
idea that antibody avidity could be an important parameter in
evaluating antigen-specific memory responses and vaccine per-
formance following immunization with novel and classical ETEC
antigens (51).
The present data suggest that additional studies will need to
take place to optimize both the route of administration, the doses
of EtpA required to achieve protection, and conditions for cofor-
mulation with other antigens. Nevertheless, our studies suggest
that it is possible to generate protective immune responses with
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FIG 6 Toxin neutralization by sera from vaccinated mice. (a) Antisera from
mice orally immunized with dmLT adjuvant prevent binding to GM1 ganglio-
sides in vitro. Sera from unvaccinated (PBS-only) mice are shown as controls.
All statistical comparisons were performed by Mann-Whitney 2-tailed non-
parametric testing (*, P  0.05; **, P  0.01; ***, P  0.001). (b) Sera from
mice immunizedwith dmLT recombinant EtpAneutralize effective delivery
of heat-labile toxin to target epithelial cells by ETEC H10407. Sera from PBS-
only vaccinated control group mice are shown at left for comparison. Addi-
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FIG 5 Avidity of EtpA-specific serum antibody following EtpA vaccination
with dmLTvarieswith both dose and route of immunization. (a) EtpA-specific
serum IgG avidity following oragastric immunization with rEtpA or intrader-
mal (ID) vaccination. (b) EtpA-specific IgA avidity index after orogastric and
intradermal vaccination. Statistical analysis results (**, P 
 0.002; ***, P 

0.0002) reflect Mann-Whitney, two-tailed nonparametric comparisons.
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earlier work with Shigella subunit proteins, and no attempt was
made here to optimize immune responses to EtpA. Clearly, the
doses of antigen delivered orally in these experiments would be
impractical for effective immunization on a large scale. However,
these studies suggest that enhanced delivery through an oral vac-
cine strain could be of benefit (52) and that EtpA could be used to
complement existing canonical approaches to development of live
attenuated ETEC vaccines (32). Not unexpectedly (53, 54), some
routes of immunization resulted in highly compartmentalized re-
sponses. While serum antibody responses to EtpA were low fol-
lowing sublingual administration of antigen, we did observe mea-
surable increases in fecal antibody (IgG and IgA) and sublingual
immunization was protective. Application of emerging methods
that enhance sublingual or buccal antigen delivery (55) could ac-
celerate development of subunit vaccines that incorporate ETEC
novel antigens.
Interestingly, emerging data do suggest that intradermal vacci-
nation with mutant LT and ETEC fimbrial tip adhesins can pro-
tect against ETEC diarrhea in a human experimental challenge
model (56), and i.d. immunization with secreted Shigella effectors
adjuvanted with dmLT was protective against experimental chal-
lenge in mice (39). Therefore, the i.d. route could conceivably be
used as a platform for development of hybrid subunit vaccines
against important enteric pathogens. Nevertheless, further effort
will be required to optimize this approach and refine antigen for-
mulations with sufficient valency to achieve broad protection
against ETEC and Shigella.
Collectively, these early data with EtpA support the concept
that this antigen could complement ongoing approaches to vac-
cine development and expand the valency of ETEC vaccines. Ad-
ditional efforts will need to focus on first defining and subse-
quently optimizing parameters that define protectionmediated by
this and other novel immunogens.
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